Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy +/- Erlotinib in EGFR-TKI Resistant NSCLC
NCT02037997Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Dec 2013
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02037997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037997.